NONOXYNOL 9
drugOn this page
Also known as C-filmCol-1492DelfenDouble checkDuragelEmkoGygelGynol 11Igepal co-630Nonoxinol 9Nonoxinolum 9Nonoxynol-9Nonoxynol-9.5NonylphenoxypolyethoxyethanolNorfox np-9NSC-758941Ortho-cremeOrtho-formsPeg-9 nonyl phenyl ether
Summary
Nonoxynol 9 (CHEMBL1410) is an approved small-molecule contraceptive drug; indicated across 3 conditions including hiv infectious disease and ebola hemorrhagic fever.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- Indications: 3 conditions
- Clinical trials: 8
- Chemistry: 616.8 Da · C33H60O10
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1410 |
| Name | NONOXYNOL 9 |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 72385 |
| ChEBI | CHEBI:53775 |
| Molecular formula | C33H60O10 |
| Molecular weight | 616.8 |
| InChIKey | FBWNMEQMRUMQSO-UHFFFAOYSA-N |
SMILES: CCCCCCCCCC1=CC=C(C=C1)OCCOCCOCCOCCOCCOCCOCCOCCOCCO
IUPAC name: 2-[2-[2-[2-[2-[2-[2-[2-[2-(4-nonylphenoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol
ChEBI definition: A tergitol polymer consisting of nonylbenzene with a nine-membered poly(ethylene glycol) moiety attached at position 4.
Pharmacological roles (ChEBI): nonionic surfactant, contraceptive drug.
Also known as: C-film, Col-1492, Delfen, Double check, Duragel, Emko, Gygel, Gynol 11, Igepal co-630, Nonoxinol 9, Nonoxinolum 9, Nonoxynol 9
Patent coverage: 5,035 distinct patent families (14,701 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 13 (assay-derived). Sample: Ubiquitin carboxyl-terminal hydrolase 2, Nuclear receptor ROR-gamma, Survival motor neuron protein, Prelamin-A/C, Ferritin light chain, Solute carrier organic anion transporter family member 1B1, Solute carrier organic anion transporter family member 1B3, Menin/Histone-lysine N-methyltransferase MLL, Cytochrome P450 3A4, Cruzipain.
Bioactivity
ChEMBL activities: 9 potent at pChembl ≥ 5 of 17 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| LMNA | 8.05 | Potency | 8.9 | nM | CHEMBL_ACT_3639488 |
| SLCO1B1 | 5.72 | Ki | 1920 | nM | CHEMBL_ACT_13800657 |
| USP2 | 5.6 | Potency | 2512 | nM | CHEMBL_ACT_4715748 |
| SLCO1B3 | 5.54 | Ki | 2870 | nM | CHEMBL_ACT_13798658 |
| SLCO1B1 | 5.46 | IC50 | 3467 | nM | CHEMBL_ACT_13800592 |
| SLCO1B3 | 5.43 | IC50 | 3715 | nM | CHEMBL_ACT_13798593 |
| SMN1 | 5.15 | Potency | 7080 | nM | CHEMBL_ACT_3878064 |
| MEN1 | 5.15 | Potency | 7080 | nM | CHEMBL_ACT_4565709 |
| P25779 | 5 | Potency | 10000 | nM | CHEMBL_ACT_4002727 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| HIV infectious disease | 3 | MONDO:0005109 | EFO:0000764 |
| Ebola hemorrhagic fever | 1 | MONDO:0005737 | EFO:0007243 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 8.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 2 |
| PHASE2 | 2 |
| Not specified | 2 |
| PHASE1 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00000926 | PHASE3 | COMPLETED | A Study of Nonoxynol-9 (N-9) and HIV Infection |
| NCT00274261 | PHASE3 | COMPLETED | Study of the Safety and Contraceptive Efficacy of C31G Compared to Conceptrol® |
| NCT00692952 | PHASE2 | COMPLETED | Effectiveness of BenZalkonium Chloride Gel as Vaginal Contraceptive: a Multicentric Randomized Controlled Trial |
| NCT01593124 | PHASE2 | COMPLETED | Identification of Novel Biomarkers of Cervicovaginal Mucosal Inflammation |
| NCT00000929 | PHASE1 | COMPLETED | A Study of the Effects of Advantage 24 on the Rectum |
| NCT00389311 | EARLY_PHASE1 | COMPLETED | A Pilot Study for Toxicity Evaluation of HIV Rectal Microbicides |
| NCT07182019 | Not specified | NOT_YET_RECRUITING | Connecting Today to Combat Social Isolation and Loneliness |
| NCT02310724 | Not specified | COMPLETED | TODAY2 Phase 2 Follow-up |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: HIV infectious disease